At a time when Chinese government is coming down heavily on polluting active pharma ingredients (API) units, the Indian bulk drug industry is doubling down efforts to get more recognition from the ...
Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI will ...
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale. This ...
Reducing its import dependence, one innovation at a time, Gujarat's pharmaceutical landscape is soon to change and evolve. With some 115 new plants getting manufacturing licences for making bulk drugs ...
The domestic pharmaceutical industry aspires to become the world’s largest supplier of drugs, targeting $120-130 billion in revenue at a CAGR of 11-12% by 2030, from $38 billion at present. In value ...
The drug firm is shutting down the unit because of the low demand for the product in the export markets AstraZeneca Pharma India will close its Active Pharmaceutical Ingredient (API) unit at Bengaluru ...
The active pharmaceutical ingredient (API) industry in Maharashtra is looking for revision and relaxation of environmental norms for its revival in the state. The industry has suggested a ...
Monday's announcement will see Dr. Reddy's API facility in Hyderabad sold to Therapiva Pvt. Ltd, a JV between a subsidiary of Neopharma Llc (parent of Neopharma Inc.) and Laxai Life Sciences. Photo: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results